{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","spread":"1.2","upperLimit":"4.7","value":"2.6"},{"groupId":"OG001","lowerLimit":"1.1","spread":"1.4","upperLimit":"6.9","value":"2.6"},{"groupId":"OG002","lowerLimit":"1.1","spread":"1.3","upperLimit":"6.9","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"35"}],"units":"Participants"}],"description":"The fold increase was measured using local lab values and is the ratio of post first dose (pre-apheresis) PB CD34+ cells/µL)/pre-plerixafor dosing PB CD34+ cells/µL)","dispersionType":"Full Range","groups":[{"description":"Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma (NHL)"},{"description":"Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Multiple Myeloma (MM)"},{"id":"OG002","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Days 4-5 (first dose of plerixafor to apheresis)","title":"Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL After First Dose of Plerixafor","type":"SECONDARY","unitOfMeasure":"ratio"}